Table 2.
Cell line | Year established/published | Patient diagnosis | Age of donor | Sex | EBV status | Cytokine dependence | Clinical Trials |
---|---|---|---|---|---|---|---|
NK3.3 | 1982 | Cloning of primary MLC-activated cells in a medium containing interleukin-2 | N/A | N/A | EBV− | IL-2-dependent | NO |
YT | 1983 | Acute lymphoblastic lymphoma (with thymoma) | 15 | Male | EBV+ | IL-2-independent | NO |
NK-92 | 1992/1994 | LGL-NHL | 50 | Male | EBV− | IL-2-dependent | Yes (Table 1) |
NKL | 1996 | NK-LGLL | 63 | Male | EBV− | IL-2-dependent | NO |
NK-YS | 1996 | NK cell lymphoma, Nasal angiocentric, Leukemic state with systemic skin infiltration | 19 | Female | EBV+ | IL-2-dependent | NO |
KHYG-1 | 1997 | Aggressive NK leukemia | 45 | Female | EBV− | IL-2-dependent | NO |
HANK1 | 1998 | Nasal-like NK/T-cell lymphoma | 46 | Female | EBV+ | IL-2-dependent | NO |
SNK-6 | 1998 | Nasal NK/T-cell lymphoma | 62 | Male | EBV+ | IL-2-dependent | NO |
SNT-8 | 1998 | Nasal NK/T-cell lymphoma | 48 | Female | EBV+ | IL-2-dependent | NO |
IMC-1 | 2004 | Aggressive NK cell leukemia | 42 | Male | EBV− | IL-2-dependent | NO |
LGL large granular lymphocyte, LGLL large granular lymphocyte leukemia, NHL non-Hodgkin’s lymphoma, EBV Epstein-Barr virus